Bupropion/dextromethorphan - Axsome Therapeutics

Drug Profile

Bupropion/dextromethorphan - Axsome Therapeutics

Alternative Names: AXS-05

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator ANTECIP BIOVENTURES
  • Developer Axsome Therapeutics
  • Class Antidepressants; Morphinans; Propiophenones; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Nicotinic receptor antagonists; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Depressive disorders
  • Phase I Agitation

Most Recent Events

  • 07 Mar 2017 Axsome Therapeutics plans a phase II/III trial to assess the efficacy and safety of bupropion/dextromethorphan in patients with Alzheimer's disease agitation in the second quarter of 2017
  • 14 Feb 2017 Bupropion/dextromethorphan - Axsome Therapeutics receives Fast Track designation for Depressive disorders [PO] (Treatment-resistant) in USA
  • 03 Jan 2017 The US FDA approves IND application for bupropion/dextromethorphan in Agitation (In Alzheimer's disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top